Human cellular restriction factors that target HIV-1 rep

**BMC** Medicine

7, 48

DOI: 10.1186/1741-7015-7-48

Citation Report

#	Article	IF	CITATIONS
1	Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. Retrovirology, 2009, 6, 111.	0.9	182
2	P09-09. Impact of immune-driven sequence variation in HIV-1 subtype C Gag-Protease on viral fitness and disease progression. Retrovirology, 2009, 6, .	0.9	O
3	HIV-1 Vaccineâ€"Many Miles to Go Before We Sleep. Journal of the Formosan Medical Association, 2009, 108, 827-829.	0.8	0
4	HIV vaccines: current status worldwide and in Africa. Aids, 2010, 24, S50-S60.	1.0	14
5	Molecular aspects of cyclophilins mediating therapeutic actions of their ligands. Cellular and Molecular Life Sciences, 2010, 67, 3467-3488.	2.4	44
6	Xenotropic Murine Leukemia Virus-Related Virus in Chronic Fatigue Syndrome and Prostate Cancer. Current Allergy and Asthma Reports, 2010, 10, 210-214.	2.4	8
7	Control of RNA silencing and localization by endolysosomes. Trends in Cell Biology, 2010, 20, 491-501.	3.6	66
8	Hematopoietic stem cells and retroviral infection. Retrovirology, 2010, 7, 8.	0.9	26
9	Murine double minute 2 as a modulator of retroviral restrictions mediated by TRIM5î±. Virology, 2010, 405, 414-423.	1.1	9
10	Cpr1 cyclophilin and Ess1 parvulin prolyl isomerases interact with the tombusvirus replication protein and inhibit viral replication in yeast model host. Virology, 2010, 406, 342-351.	1.1	60
11	The challenge of obtaining therapeutic levels of genetically modified hematopoietic stem cells in $\hat{l}^2\hat{a}$ thalassemia patients. Annals of the New York Academy of Sciences, 2010, 1202, 69-74.	1.8	15
12	Identification of <sup>81</sup> LGxGxxlxW <sup>89</sup> and <sup>171</sup> EDRW <sup>174</sup> Domains from Human Immunodeficiency Virus Type 1 Vif That Regulate APOBEC3G and APOBEC3F Neutralizing Activity. Journal of Virology, 2010, 84, 5741-5750.	1.5	49
13	Ebola Virus Glycoprotein Counteracts BST-2/Tetherin Restriction in a Sequence-Independent Manner That Does Not Require Tetherin Surface Removal. Journal of Virology, 2010, 84, 7243-7255.	1.5	107
14	Identification of Dominant Negative Human Immunodeficiency Virus Type 1 Vif Mutants That Interfere with the Functional Inactivation of APOBEC3G by Virus-Encoded Vif. Journal of Virology, 2010, 84, 5201-5211.	1.5	30
15	Identification of a Critical $T(Q/D/E)x < sub>5 < /sub> ADx < sub>2 < /sub> (I/L) Motif from Primate Lentivirus Vif Proteins That Regulate APOBEC3G and APOBEC3F Neutralizing Activity. Journal of Virology, 2010, 84, 8561-8570.$	1.5	33
16	Advances in the Field of Lentivector-based Transduction of T and B Lymphocytes for Gene Therapy. Molecular Therapy, 2010, 18, 1748-1757.	3.7	62
17	Viral replication is enhanced by an HIV-1 intersubtype recombination-derived Vpu protein. Virology Journal, 2010, 7, 259.	1.4	10
18	Role of microRNAs in HTLV-1 infection and transformation. Molecular Aspects of Medicine, 2010, 31, 367-382.	2.7	37

#	ARTICLE	IF	CITATIONS
19	HIV-1 Vpu targets cell surface markers CD4 and BST-2 through distinct mechanisms. Molecular Aspects of Medicine, 2010, 31, 407-417.	2.7	38
20	Structural Basis of HIV-1 Tethering to Membranes by the BST-2/Tetherin Ectodomain. Cell Host and Microbe, 2010, 7, 314-323.	5.1	142
21	The Interferon-Inducible Host Factor Bone Marrow Stromal Antigen 2/Tetherin Restricts Virion Release, but Is It Actually a Viral Restriction Factor?. Journal of Interferon and Cytokine Research, 2011, 31, 137-144.	0.5	31
22	MicroRNAs and human retroviruses. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2011, 1809, 686-693.	0.9	73
23	Retroviral restriction and dependency factors in primates and carnivores. Veterinary Immunology and Immunopathology, 2011, 143, 179-189.	0.5	22
24	Macaque-Tropic HIV-1 Derivatives: A Novel Experimental Approach to Understand Viral Replication and Evolution in Vivo. , 0, , .		10
26	<i>TRIM5</i> allelic polymorphism in macaque species/populations of different geographic origins: its impact on SIV vaccine studies. Tissue Antigens, 2011, 78, 256-262.	1.0	24
27	Stem cell-based anti-HIV gene therapy. Virology, 2011, 411, 260-272.	1.1	47
28	Emerging picture of host chaperone and cyclophilin roles in RNA virus replication. Virology, 2011, 411, 374-382.	1.1	170
29	High-throughput assay to identify inhibitors of Vpu-mediated down-regulation of cell surface BST-2. Antiviral Research, 2011, 91, 321-329.	1.9	44
30	Pathogenic Mechanisms of HIV Disease. Annual Review of Pathology: Mechanisms of Disease, 2011, 6, 223-248.	9.6	312
31	New developments in the induction and antiviral effectors of type I interferon. Current Opinion in Immunology, 2011, 23, 57-64.	2.4	134
32	A proteomic study of TAR-RNA binding protein (TRBP)-associated factors. Cell and Bioscience, 2011, 1, 9.	2.1	27
33	Evidence and controversies on the role of XMRV in prostate cancer and chronic fatigue syndrome. Reviews in Medical Virology, 2011, 21, 3-17.	3.9	19
34	Multiple levels of PKR inhibition during HIVâ€1 replication. Reviews in Medical Virology, 2011, 21, 42-53.	3.9	60
35	Identification of Amino Acids in the Human Tetherin Transmembrane Domain Responsible for HIV-1 Vpu Interaction and Susceptibility. Journal of Virology, 2011, 85, 932-945.	1.5	72
36	Human and Rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H Demonstrate a Conserved Capacity To Restrict Vif-Deficient HIV-1. Journal of Virology, 2011, 85, 11220-11234.	1.5	310
37	TRIM22 Inhibits HIV-1 Transcription Independently of Its E3 Ubiquitin Ligase Activity, Tat, and NF-ÎB-Responsive Long Terminal Repeat Elements. Journal of Virology, 2011, 85, 5183-5196.	1.5	87

#	ARTICLE	IF	CITATIONS
38	The TRIM5α Genotype of Rhesus Macaques Affects Acquisition of Simian Immunodeficiency Virus SIVsmE660 Infection after Repeated Limiting-Dose Intrarectal Challenge. Journal of Virology, 2011, 85, 9637-9640.	1.5	60
39	Memory CCR6+CD4+ T Cells Are Preferential Targets for Productive HIV Type 1 Infection Regardless of Their Expression of Integrin $\hat{I}^2$ 7. Journal of Immunology, 2011, 186, 4618-4630.	0.4	126
40	Analysis of Human APOBEC3H Haplotypes and Anti-Human Immunodeficiency Virus Type 1 Activity. Journal of Virology, 2011, 85, 3142-3152.	1.5	99
41	Atomic Force Microscopy Studies Provide Direct Evidence for Dimerization of the HIV Restriction Factor APOBEC3G. Journal of Biological Chemistry, 2011, 286, 3387-3395.	1.6	91
42	Completion of Hepatitis C Virus Replication Cycle in Heterokaryons Excludes Dominant Restrictions in Human Non-liver and Mouse Liver Cell Lines. PLoS Pathogens, 2011, 7, e1002029.	2.1	23
43	Frequent and Recent Human Acquisition of Simian Foamy Viruses Through Apes' Bites in Central Africa. PLoS Pathogens, 2011, 7, e1002306.	2.1	103
44	SAMHD1-Deficient CD14+ Cells from Individuals with Aicardi-GoutiÃ"res Syndrome Are Highly Susceptible to HIV-1 Infection. PLoS Pathogens, 2011, 7, e1002425.	2.1	225
45	The TPR Domain in the Host Cyp40-like Cyclophilin Binds to the Viral Replication Protein and Inhibits the Assembly of the Tombusviral Replicase. PLoS Pathogens, 2012, 8, e1002491.	2.1	31
46	Multi-Scale Modeling of HIV Infection in vitro and APOBEC3G-Based Anti-Retroviral Therapy. PLoS Computational Biology, 2012, 8, e1002371.	1.5	18
47	MicroRNA-Mediated Restriction of HIV-1 in Resting CD4+ T Cells and Monocytes. Viruses, 2012, 4, 1390-1409.	1.5	39
48	Retroviral GAG proteins recruit AGO2 on viral RNAs without affecting RNA accumulation and translation. Nucleic Acids Research, 2012, 40, 775-786.	6.5	32
49	Cyclophilin involvement in the replication of hepatitis C virus and other viruses. Biological Chemistry, 2012, 393, 579-587.	1.2	19
50	TRIM5 and the Regulation of HIV-1 Infectivity. Molecular Biology International, 2012, 2012, 1-6.	1.7	16
51	The MicroRNA Regulatory Network in Normal- and HTLV-1-Transformed T Cells. Advances in Cancer Research, 2012, 113, 45-83.	1.9	6
52	How Samhd1 changes our view of viral restriction. Trends in Immunology, 2012, 33, 26-33.	2.9	62
53	Evolutionary and Functional Analyses of the Interaction between the Myeloid Restriction Factor SAMHD1 and the Lentiviral Vpx Protein. Cell Host and Microbe, 2012, 11, 205-217.	5.1	169
54	Impact of cellular autophagy on viruses: Insights from hepatitis B virus and human retroviruses. Journal of Biomedical Science, 2012, 19, 92.	2.6	51
55	Emerging complexities of APOBEC3G action on immunity and viral fitness during HIV infection and treatment. Retrovirology, 2012, 9, 35.	0.9	32

#	Article	IF	CITATIONS
56	Genetic manipulation of schistosomes $\hat{a} \in \text{``progress with integration competent vectors. Parasitology, 2012, 139, 641-650.}$	0.7	15
57	Evaluation of the interactions of HIV-1 integrase with small ubiquitin-like modifiers and their conjugation enzyme Ubc9. International Journal of Molecular Medicine, 2012, 30, 1053-1060.	1.8	12
58	Control of Innate and Adaptive Immune Responses during Infectious Diseases. , 2012, , .		4
59	Expression Analysis of LEDGF/p75, APOBEC3G, TRIM5alpha, and Tetherin in a Senegalese Cohort of HIV-1-Exposed Seronegative Individuals. PLoS ONE, 2012, 7, e33934.	1.1	28
61	Molecular Understanding of HIV-1 Latency. Advances in Virology, 2012, 2012, 1-14.	0.5	29
62	Species tropism of HIV-1 modulated by viral accessory proteins. Frontiers in Microbiology, 2012, 3, 267.	1.5	10
63	Identification of the platelet-derived chemokine CXCL4/PF-4 as a broad-spectrum HIV-1 inhibitor. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 9569-9574.	3.3	90
64	Delineating HIV-Associated Neurocognitive Disorders Using Transgenic Models: The Neuropathogenic Actions of Vpr. Journal of NeuroImmune Pharmacology, 2012, 7, 319-331.	2.1	25
65	Quantification of HIV-based lentiviral vectors: influence of several cell type parameters on vector infectivity. Archives of Virology, 2012, 157, 217-223.	0.9	7
66	HIV-1 transcription and latency: an update. Retrovirology, 2013, 10, 67.	0.9	271
67	The HIV-1 pandemic: does the selective sweep in chimpanzees mirror humankind's future?. Retrovirology, 2013, 10, 53.	0.9	39
68	TLR-4 engagement of dendritic cells confers a BST-2/tetherin-mediated restriction of HIV-1 infection to CD4+T cells across the virological synapse. Retrovirology, 2013, 10, 6.	0.9	26
69	HIV accessory proteins versus host restriction factors. Current Opinion in Virology, 2013, 3, 692-699.	2.6	111
70	SIV replication is directly downregulated by four antiviral miRNAs. Retrovirology, 2013, 10, 95.	0.9	28
71	The Conserved Set of Host Proteins Incorporated into HIV-1 Virions Suggests a Common Egress Pathway in Multiple Cell Types. Journal of Proteome Research, 2013, 12, 2045-2054.	1.8	54
72	Cyclophilin Inhibitors for Hepatitis C Therapy. Clinics in Liver Disease, 2013, 17, 129-139.	1.0	23
73	Gag-CA Q110D mutation elicits TRIM5-independent enhancement ofÂHIV-1mt replication in macaque cells. Microbes and Infection, 2013, 15, 56-65.	1.0	27
74	Curing a viral infection by targeting the host: The example of cyclophilin inhibitors. Antiviral Research, 2013, 99, 68-77.	1.9	101

#	Article	IF	Citations
75	The Role of CD81 in HCV and Plasmodium Infection. , 2013, , 345-386.		0
76	T Cells Target APOBEC3 Proteins in Human Immunodeficiency Virus Type 1-Infected Humans and Simian Immunodeficiency Virus-Infected Indian Rhesus Macaques. Journal of Virology, 2013, 87, 6073-6080.	1.5	6
77	Cyclophilin A Binds to the Viral RNA and Replication Proteins, Resulting in Inhibition of Tombusviral Replicase Assembly. Journal of Virology, 2013, 87, 13330-13342.	1.5	35
78	The Host Proteins Transportin SR2/TNPO3 and Cyclophilin A Exert Opposing Effects on HIV-1 Uncoating. Journal of Virology, 2013, 87, 422-432.	1.5	113
79	Interleukin-1 and Tumor Necrosis Factor-α Trigger Restriction of Hepatitis B Virus Infection via a Cytidine Deaminase Activation-induced Cytidine Deaminase (AID). Journal of Biological Chemistry, 2013, 288, 31715-31727.	1.6	140
80	NEAT1 Long Noncoding RNA and Paraspeckle Bodies Modulate HIV-1 Posttranscriptional Expression. MBio, 2013, 4, e00596-12.	1.8	327
81	Restriction of Virus Infection but Not Catalytic dNTPase Activity Is Regulated by Phosphorylation of SAMHD1. Journal of Virology, 2013, 87, 11516-11524.	1.5	139
82	Variants in ZNRD1 Gene Predict HIV-1/AIDS Disease Progression in a Han Chinese Population in Taiwan. PLoS ONE, 2013, 8, e67572.	1.1	6
83	Tombusvirus-yeast interactions identify conserved cell-intrinsic viral restriction factors. Frontiers in Plant Science, 2014, 5, 383.	1.7	23
84	HIV-1 Vpu â€" an ion channel in search of a job. Biochimica Et Biophysica Acta - Biomembranes, 2014, 1838, 1074-1081.	1.4	40
85	Elevated APOBEC3B Correlates with Poor Outcomes for Estrogen-Receptor-Positive Breast Cancers. Hormones and Cancer, 2014, 5, 405-413.	4.9	140
86	Ring finger protein 39 genetic variants associate with HIV-1 plasma viral loads and its replication in cell culture. Cell and Bioscience, 2014, 4, 40.	2.1	3
87	Human coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive cyclosporine A-derivatives including Alisporivir. Virus Research, 2014, 184, 44-53.	1.1	122
88	MicroRNA regulation of p21 and TASK1 cellular restriction-factors enhances HIV-1 infection. Journal of Cell Science, 2015, 128, 1607-16.	1.2	51
89	Interaction between Nef and INI1/SMARCB1 augments replicability of HIV-1 in resting human peripheral blood mononuclear cells. Archives of Virology, 2015, 160, 727-737.	0.9	2
90	IFI44 suppresses HIV-1 LTR promoter activity and facilitates its latency. Virology, 2015, 481, 142-150.	1.1	97
91	Non-coding RNAs and HIV: viral manipulation of host dark matter to shape the cellular environment. Frontiers in Genetics, 2015, 6, 108.	1.1	23
92	Cellular Innate Immunity and Restriction of Viral Infection: Implications for Lentiviral Gene Therapy in Human Hematopoietic Cells. Human Gene Therapy, 2015, 26, 201-209.	1.4	30

#	Article	IF	CITATIONS
93	ASK1 restores the antiviral activity of APOBEC3G by disrupting HIV-1 Vif-mediated counteraction. Nature Communications, 2015, 6, 6945.	5.8	32
94	Role of Host Proteins in HIV-1 Early Replication. , 2016, , .		2
95	HIV-1 subtype B: Traces of a pandemic. Virology, 2016, 495, 173-184.	1.1	50
96	The MHC-II transactivator CIITA inhibits Tat function and HIV-1 replication in human myeloid cells. Journal of Translational Medicine, 2016, 14, 94.	1.8	20
97	Computational Model and Dynamics of Monomeric Full-Length APOBEC3G. ACS Central Science, 2017, 3, 1180-1188.	<b>5.</b> 3	32
98	Tripartite Motif 22 and Class II Transactivator Restriction Factors: Unveiling Their Concerted Action against Retroviruses. Frontiers in Immunology, 2017, 8, 1362.	2.2	8
99	Cyclophilin A as a target in the treatment of cytomegalovirus infections. Antiviral Chemistry and Chemotherapy, 2018, 26, 204020661881141.	0.3	8
100	The Neuropeptides Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-Activating Polypeptide Control HIV-1 Infection in Macrophages Through Activation of Protein Kinases A and C. Frontiers in Immunology, 2018, 9, 1336.	2.2	15
101	HIV-1 infection increases microRNAs that inhibit Dicer1, HRB and HIV-EP2, thereby reducing viral replication. PLoS ONE, 2019, 14, e0211111.	1.1	22
103	APOBEC3B Potently Restricts HIV-2 but Not HIV-1 in a Vif-Dependent Manner. Journal of Virology, 2021, 95, e0117021.	1.5	3
104	Natural SIV Infection., 2012,, 3-45.		3
105	CD4+ T cells from elite controllers resist HIV-1 infection by selective upregulation of p21. Journal of Clinical Investigation, 2011, 121, 1549-1560.	3.9	156
106	Perturbation of the P-Body Component Mov10 Inhibits HIV-1 Infectivity. PLoS ONE, 2010, 5, e9081.	1.1	105
107	Localization and Sub-Cellular Shuttling of HTLV-1 Tax with the miRNA Machinery. PLoS ONE, 2012, 7, e40662.	1.1	25
108	APOBEC3G-Augmented Stem Cell Therapy to Modulate HIV Replication: A Computational Study. PLoS ONE, 2013, 8, e63984.	1.1	10
109	HIV and Cytokines. , 2011, , 139-153.		0
110	T Cell Responses During Human Immunodeficiency Virus (HIV)-1 Infection., 2012,, 141-169.		0
111	Host Molecular Chaperones: Cell Surface Receptors for Viruses. Heat Shock Proteins, 2013, , 293-307.	0.2	1

#	Article	IF	CITATIONS
112	HIV-1 Biology at the Protein Level. , 2016, , 5-26.		0
113	Resistance against hIV-1: role of chemokine receptor, CCR5 and restriction factor, APOBEC3G. International Journal of Pharma and Bio Sciences, 2017, 8, .	0.1	0
114	Improved lentiviral vector titers from a multi-gene knockout packaging line. Molecular Therapy - Oncolytics, 2021, 23, 582-592.	2.0	8
116	The Myeloid-Specific Transcription Factor PU.1 Upregulates Mannose Receptor Expression but Represses Basal Activity of the HIV-LTR Promoter. Journal of Virology, 2022, 96, .	1.5	4
118	<scp>DNAJB8</scp> facilitates autophagicâ€lysosomal degradation of viral Vif protein and restricts <scp>HIV</scp> â€l virion infectivity by rescuing <scp>APOBEC3G</scp> expression in host cells. FASEB Journal, 2023, 37, .	0.2	2